- Home
- URGN vs GILT Comparison
URGN vs GILT Comparison
Compare URGN & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- GILT
- Stock Information
- Founded
- URGN 2004
- GILT 1987
- Country
- URGN United States
- GILT Israel
- Employees
- URGN N/A
- GILT N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- GILT Radio And Television Broadcasting And Communications Equipment
- Sector
- URGN Health Care
- GILT Technology
- Exchange
- URGN Nasdaq
- GILT Nasdaq
- Market Cap
- URGN 830.4M
- GILT 894.0M
- IPO Year
- URGN 2017
- GILT 1993
- Fundamental
- Price
- URGN $20.62
- GILT $14.29
- Analyst Decision
- URGN Strong Buy
- GILT Strong Buy
- Analyst Count
- URGN 8
- GILT 1
- Target Price
- URGN $28.50
- GILT $11.00
- AVG Volume (30 Days)
- URGN 921.6K
- GILT 821.5K
- Earning Date
- URGN 11-06-2025
- GILT 11-12-2025
- Dividend Yield
- URGN N/A
- GILT N/A
- EPS Growth
- URGN N/A
- GILT 12.49
- EPS
- URGN N/A
- GILT 0.39
- Revenue
- URGN $94,238,000.00
- GILT $349,746,000.00
- Revenue This Year
- URGN $36.41
- GILT $47.18
- Revenue Next Year
- URGN $118.04
- GILT $13.80
- P/E Ratio
- URGN N/A
- GILT $36.88
- Revenue Growth
- URGN 10.85
- GILT 19.67
- 52 Week Low
- URGN $3.42
- GILT $4.86
- 52 Week High
- URGN $21.71
- GILT $15.24
- Technical
- Relative Strength Index (RSI)
- URGN 63.69
- GILT 57.69
- Support Level
- URGN $19.17
- GILT $14.13
- Resistance Level
- URGN $21.00
- GILT $14.58
- Average True Range (ATR)
- URGN 1.12
- GILT 0.61
- MACD
- URGN 0.35
- GILT -0.10
- Stochastic Oscillator
- URGN 83.19
- GILT 56.42
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.